eLum Technologies

Executive Summary

eLum Technologies is an early-stage endovascular medical device company headquartered in Menlo Park, California, founded in 2015. The company operates at the intersection of medical devices and neuroscience, focusing on developing disruptive technologies to address a range of endovascular diseases, particularly in neurovascular interventions. As a private company with limited public information, eLum has not disclosed its funding, valuation, or stage of development. Given its early-stage status, the company faces significant technical, regulatory, and commercial risks. However, its focus on innovating within the growing neurovascular market—driven by aging demographics and unmet clinical needs—positions it for potential upside if it achieves key milestones. The company’s success will depend on progress in product development, clinical validation, regulatory approvals, and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial30% success
• Q2 2026Series A Funding Round50% success
• Q3 2026Strategic Partnership with Major Medical Center40% success